Kisqali Label Expansion Will Double Market Size Opportunity
The US FDA approved the drug with a broad label for patients with HR+/HER2- early breast cancer at high risk of recurrence, a potentially multibillion-dollar opportunity.
The US FDA approved the drug with a broad label for patients with HR+/HER2- early breast cancer at high risk of recurrence, a potentially multibillion-dollar opportunity.